Market Overview:
The global interleukin 1 (IL1) market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of various diseases, rising awareness about IL1 inhibitors and growing demand for novel therapies. The global IL1 market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into APX-002, canakinumab, diacerein CR, IR-1000 and others. On the basis of application, the market is segmented into esophageal cancer, fallopian tube cancer bladder cancer bechcer disease and others.
 Industry Outlook.svg)
Product Definition:
Interleukin 1 (IL1) is a cytokine that is produced in the body in response to infection or injury. Cytokines are proteins that help regulate the immune system and inflammation. IL1 plays a role in the inflammatory response and can promote fever, muscle pain, and other symptoms of illness.
APX-002:
Interleukin 1 (IL1) is a cytokine that belongs to the interleukin family. Interleukins are low-molecular-weight proteins that are produced by cells of the immune system and also by some non-immune cells such as fibroblasts, endothelial cells, keratinocytes, and neuroendocrine tissues.
Canakinumab:
Canakinumab (AKA Canakinumab-vfr) is a fully human interleukin 1 therapeutics. It was approved by the U.S. FDA in 2013 for treatment of atopic dermatitis and in 2014 for psoriasis as well, making it the first interleukin 1 drug to receive approval from both American FDA and European Commission (EU).
Application Insights:
The application segment includes esophageal cancer, fallopian tube cancer, bladder cancer, bechcer disease, and others. Esophageal cancer was the largest revenue generating segment in 2017 owing to high product usage for the treatment of advanced esophageal tumors. The use of interleukin 1 for treating esophageal tumor is based on its ability to inhibit tumor angiogenesis by reducing the expression of vascular endothelial growth factor (VEGF) which is a key step in anti-cancer therapy.
Interleukin 1 has been used extensively for treating patients with locally advanced or metastatic adenocarcinoma of the pancreas and other pancreatic cancers as well as non-metastatic prostate carcinoma along with its associated symptoms such as pain and nausea due to radiation sickness syndrome that often occurs during this course of treatment.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high adoption rate for novel therapeutics, and increasing healthcare expenditure in this region. In addition, favorable reimbursement policies are also aiding growth in this region. For instance, under the Affordable Care Act (ACA), insurance companies are required to cover at least 80% cost of medicines that treat cancer or HIV/AIDS.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and improving economic conditions especially in developing countries such as China and India which have a high unmet clinical needs due interleukin 1-associated diseases (ID). Moreover, growing awareness about early diagnosis will boost regional demand further over the forecast period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the Interleukin 1 (IL1) market. IL1 is a pro-inflammatory cytokine that plays an important role in the pathogenesis of autoimmune diseases. This is expected to drive the demand for IL1 inhibitors and therapies over the forecast period.
- Rising prevalence of chronic inflammatory conditions: The rising prevalence of chronic inflammatory conditions, such as rheumatoid arthritis, Crohn’s disease, and psoriasis, is another major factor driving the growth of the Interleukin 1 (IL1) market. IL1 has been found to play a significant role in these conditions and its inhibition can provide relief from their symptoms.
- Growing awareness about benefits offered by IL1 inhibitors: There is growing awareness among patients and healthcare professionals about the benefits offered by IL1 inhibitors in treating various inflammatory disorders. This is likely to boost demand for these drugs over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Interleukin 1 (IL1) Market Research Report
By Type
APX-002, Canakinumab, Diacerein CR, IR-1000, Others
By Application
Esophageal Cancer, Fallopian Tube Cancer, Bladder Cancer, Bechcer Disease, Others
By Companies
Optimum Therapeutics LLC, Orphit SAS, Peptinov SAS, AbbVie Inc, Swedish Orphan Biovitrum AB, TWi Biotechnology Inc, XBiotech Inc, Cell Medica Ltd, Exicure Inc, Immune Response BioPharma Inc, Optimum Therapeutics LLC, Omnitura Therapeutics Inc, Opsona Therapeutics Ltd, Anacor Pharmaceuticals Inc, Apexigen Inc, R Pharm, Regeneron Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Interleukin 1 (IL1) Market Report Segments:
The global Interleukin 1 (IL1) market is segmented on the basis of:
Types
APX-002, Canakinumab, Diacerein CR, IR-1000, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Esophageal Cancer, Fallopian Tube Cancer, Bladder Cancer, Bechcer Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Optimum Therapeutics LLC
- Orphit SAS
- Peptinov SAS
- AbbVie Inc
- Swedish Orphan Biovitrum AB
- TWi Biotechnology Inc
- XBiotech Inc
- Cell Medica Ltd
- Exicure Inc
- Immune Response BioPharma Inc
- Optimum Therapeutics LLC
- Omnitura Therapeutics Inc
- Opsona Therapeutics Ltd
- Anacor Pharmaceuticals Inc
- Apexigen Inc
- R Pharm
- Regeneron Pharmaceuticals Inc
 Market Overview.svg)
Highlights of The Interleukin 1 (IL1) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- APX-002
- Canakinumab
- Diacerein CR
- IR-1000
- Others
- By Application:
- Esophageal Cancer
- Fallopian Tube Cancer
- Bladder Cancer
- Bechcer Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interleukin 1 (IL1) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IL1 is a cytokine that helps the body fight infection.
Some of the major players in the interleukin 1 (il1) market are Optimum Therapeutics LLC, Orphit SAS, Peptinov SAS, AbbVie Inc, Swedish Orphan Biovitrum AB, TWi Biotechnology Inc, XBiotech Inc, Cell Medica Ltd, Exicure Inc, Immune Response BioPharma Inc, Optimum Therapeutics LLC, Omnitura Therapeutics Inc, Opsona Therapeutics Ltd, Anacor Pharmaceuticals Inc, Apexigen Inc, R Pharm, Regeneron Pharmaceuticals Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Interleukin 1 (IL1) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Interleukin 1 (IL1) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Interleukin 1 (IL1) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Interleukin 1 (IL1) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Interleukin 1 (IL1) Market Size & Forecast, 2020-2028
4.5.1 Interleukin 1 (IL1) Market Size and Y-o-Y Growth
4.5.2 Interleukin 1 (IL1) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 APX-002
5.2.2 Canakinumab
5.2.3 Diacerein CR
5.2.4 IR-1000
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Esophageal Cancer
6.2.2 Fallopian Tube Cancer
6.2.3 Bladder Cancer
6.2.4 Bechcer Disease
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Interleukin 1 (IL1) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Interleukin 1 (IL1) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 APX-002
9.6.2 Canakinumab
9.6.3 Diacerein CR
9.6.4 IR-1000
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Esophageal Cancer
9.10.2 Fallopian Tube Cancer
9.10.3 Bladder Cancer
9.10.4 Bechcer Disease
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 APX-002
10.6.2 Canakinumab
10.6.3 Diacerein CR
10.6.4 IR-1000
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Esophageal Cancer
10.10.2 Fallopian Tube Cancer
10.10.3 Bladder Cancer
10.10.4 Bechcer Disease
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 APX-002
11.6.2 Canakinumab
11.6.3 Diacerein CR
11.6.4 IR-1000
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Esophageal Cancer
11.10.2 Fallopian Tube Cancer
11.10.3 Bladder Cancer
11.10.4 Bechcer Disease
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 APX-002
12.6.2 Canakinumab
12.6.3 Diacerein CR
12.6.4 IR-1000
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Esophageal Cancer
12.10.2 Fallopian Tube Cancer
12.10.3 Bladder Cancer
12.10.4 Bechcer Disease
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 APX-002
13.6.2 Canakinumab
13.6.3 Diacerein CR
13.6.4 IR-1000
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Esophageal Cancer
13.10.2 Fallopian Tube Cancer
13.10.3 Bladder Cancer
13.10.4 Bechcer Disease
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Interleukin 1 (IL1) Market: Competitive Dashboard
14.2 Global Interleukin 1 (IL1) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Optimum Therapeutics LLC
14.3.2 Orphit SAS
14.3.3 Peptinov SAS
14.3.4 AbbVie Inc
14.3.5 Swedish Orphan Biovitrum AB
14.3.6 TWi Biotechnology Inc
14.3.7 XBiotech Inc
14.3.8 Cell Medica Ltd
14.3.9 Exicure Inc
14.3.10 Immune Response BioPharma Inc
14.3.11 Optimum Therapeutics LLC
14.3.12 Omnitura Therapeutics Inc
14.3.13 Opsona Therapeutics Ltd
14.3.14 Anacor Pharmaceuticals Inc
14.3.15 Apexigen Inc
14.3.16 R Pharm
14.3.17 Regeneron Pharmaceuticals Inc
